Development of biosimilar monoclonal antibodies

Academic head of project management: Bálint Bálint László

  • Title of project: Bioszimiláris monoklonális antitestek fejlesztése
  • Type of grant: R&D contract research
  • Description: The use of monoclonal antibodies has been growing continuously in the treatment of oncological and immune diseases. The patent coverage of several products will expire soon and so there will be an opportunity to develop biosimilar monoclonal antibodies. The tasks specified in the research program include basic, industrial, and experimental research activities alike, which can be realized due to their complexity only by a consortium made up of the leading research institutions of the sector. The objective of Richter Gedeon Nyrt. and its partners is to produce drug molecules greatly resembling the originals with the use of modern procedures and ingredients. With the development of the new, cost-efficient technology, the patients will get access to modern drugs at a lower price. With the developed products we will start the clinical trials prescribed by the relevant authorities.
  • The duration of the project: January 1, 2014 – December 31, 2017
  • Actual total costs: 140.000.000 (HUF)
  • Type of research: Applied
  • Consortium details:
    • Lead applicant: Richter Gedeon NyRt.
    • Consortium partner:
      • University of Debrecen
      • HAS Research Center for Natural Sciences
      • Eötvös Loránd University

Updated: 2017.08.15.


Dear User!

 

The University of Debrecen considers the protection of personal data and the information provided to be of paramount importance. We hereby inform you that the University of Debrecen has reviewed its processes and incorporated the requirements of GDPR into his own data management and data protection activities, which entered into force on may 25,2018. The personal data of the users has been carefully handled by the University of Debrecen, it complies with the applicable data management regulations.Following the requirements of GDPR, we updated our Privacy Statement, which you can access by clicking on the link below: Privacy Policy.